Psilocybin and psilocin clinical trials

Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study University of Wisconsin, Madison · 2026-07-01 · NCT07360301 Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms Centre Hospitalier Universitaire de Nīmes · 2026-06-30 · NCT07638553 A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD) Sunstone Medical · 2026-06-30 · NCT06902974 A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older Adults University of Colorado, Denver · 2026-06-29 · NCT07516405 The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease Yale University · 2026-06-28 · NCT07610369 5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder Johns Hopkins University · 2026-06-28 · NCT05452772 Psilocybin-Assisted Massed Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label Trial Unity Health Toronto · 2026-06-25 · NCT06386003 Psilocybin-Assisted Therapy for Physician Well-Being and Burnout: Feasibility, Safety, Clinical Effectiveness and Biomarkers of Response [PAT-B (Psilocybin-Assisted Therapy for Physician Well-Being and Burnout)] University of California, San Diego · 2026-06-25 · NCT06814522 Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects University Hospital, Basel, Switzerland · 2026-06-24 · NCT06884514 A Pilot Mechanistic RCT of Psilocybin With Mindfulness-based Therapy vs Support for Posttraumatic Stress Disorder (PTSD) Anthony P King · 2026-06-24 · NCT07104916 Psilocybin Administration With 5-HT1a Blockade Johns Hopkins University · 2026-06-24 · NCT07565493 TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy M.D. Anderson Cancer Center · 2026-06-23 · NCT06200155 TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors M.D. Anderson Cancer Center · 2026-06-23 · NCT06801041 NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy M.D. Anderson Cancer Center · 2026-06-23 · NCT07227909 Effects of Psilocybin Microdosing on Cognition, Mood and Quality of Life: A Pilot Study Yale University · 2026-06-22 · NCT07449351 Psilocybin-assisted Existential, Attachment and Relational (PEARL) Therapy for Caregivers of Patients With Advanced Cancer: A Phase II Open-Label Trial University Health Network, Toronto · 2026-06-22 · NCT07048743 Psilocybin-Assisted Therapy for Prolonged Grief University of Virginia · 2026-06-22 · NCT06724289 Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring Opioids Roswell Park Cancer Institute · 2026-06-21 · NCT06827054 Psilocybin for PTSD With or Without Psychotherapy: A Pilot Study of Safety and Efficacy Johns Hopkins University · 2026-06-21 · NCT06407635 Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Phase II Open-Label Trial University Health Network, Toronto · 2026-06-21 · NCT06416085 The Acute Effects of Psilocybin on Cognition, Memory, and Brain Function Manoj Doss · 2026-06-14 · NCT07079852 Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder: A Double-Blind, Dose-Comparison Concurrent Control Randomized Trial Brigham and Women's Hospital · 2026-06-14 · NCT07296094 Psilocybin as a Treatment for Chronic Pain in Smokers Yale University · 2026-06-08 · NCT07118332 PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin Pretreatment Johns Hopkins University · 2026-06-07 · NCT07610135 A Double Blind, Randomized Trial Investigating the Safety, Feasibility, and Mechanisms of Psychedelics in Healthy Older Adults With Low Well-being as Moderated by Biomarkers for Preclinical Alzheimer's Disease Jennifer Mitchell · 2026-06-07 · NCT07386730 Multivariate Neural and Physiological Correlates of Psychedelic Sub-states: a Within-subjects, Healthy Volunteer Study With Experience-sampling Robin Carhart-Harris, PhD, MA · 2026-06-04 · NCT05698511 A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in Veterans VA Office of Research and Development · 2026-06-04 · NCT07226232 Effects of Repeated Dosing of Psilocybin on Obsessive-Compulsive Disorder: A Randomized, Waitlist-Controlled Study Yale University · 2026-06-03 · NCT05370911 2 x 2 Factorial, Double-blind, Randomized Trial of 'Set and Setting': a Translational Study in Healthy Volunteers Robin Carhart-Harris, PhD, MA · 2026-06-03 · NCT06626139 The Role of the Subjective Experience in Supporting Positive Effects Following Psilocybin: a Randomized, Controlled Clinical Trial Using Risperidone in Healthy Adults University of Calgary · 2026-06-01 · NCT06768944 Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST) Centre for Addiction and Mental Health · 2026-05-31 · NCT06512220 A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD) Usona Institute · 2026-05-31 · NCT06308653 Psilocybin: Capturing Brain Mechanisms of Motivation and Neurocognition in Individuals With Opioid Use Disorder University of Pennsylvania · 2026-05-31 · NCT06810310 A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and Depression University of Washington · 2026-05-28 · NCT07336238 Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual Anhedonia NYU Langone Health · 2026-05-26 · NCT07607938 The Safety and Acceptability of Psilocybin With Support and With Massed Prolonged Exposure Therapy for PTSD Emory University · 2026-05-25 · NCT07332143 Effects of Psilocybin With Psychological Support on Anhedonia in Treatment-resistant Depression: a Randomized Controlled Pilot Trial University of Colorado, Denver · 2026-05-21 · NCT06230757 Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder University of New Mexico · 2026-05-21 · NCT07506395 A Pilot Mechanistic Study of Psilocybin-Assisted Therapy as a Treatment for Depression Washington University School of Medicine · 2026-05-19 · NCT07582120 Psilocybin-assisted Cognitive Behavioral Therapy for Depression University of California, Los Angeles · 2026-05-18 · NCT05227612 Psilocybin-facilitated Treatment for Cocaine Use University of Alabama at Birmingham · 2026-05-17 · NCT02037126 Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical Trial Centre for Addiction and Mental Health · 2026-05-17 · NCT06299319 Exploring the Safety, Acceptability, and Efficacy of Psilocybin Among Non-Small Cell Lung Cancer Patients With Major Depressive Disorder: A Proof-of-Concept Trial (DREAM LUNG STUDY) Alan Davis · 2026-05-13 · NCT07216404 Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence University of Calgary · 2026-05-13 · NCT06885996 A Randomized Double-masked Dose-controlled Trial to Assess the Tolerability, Safety, Subjective Experience, and Efficacy of Repeated Administration of Three Different Doses of Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder. Francisco A Moreno · 2026-05-11 · NCT07347405 Safety and Feasibility of Psilocybin in Methamphetamine Use Disorder in a Community-Based Sample University of Wisconsin, Madison · 2026-05-11 · NCT05322954 A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder COMPASS Pathways · 2026-05-11 · NCT07570654 The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD. University Medical Center Groningen · 2026-05-07 · NCT06782724 Does Psilocybin Require Psychedelic Effects to Treat Depression? A4-Week, Double-Blind, Proof-of-Concept Randomized Controlled Trial Centre for Addiction and Mental Health · 2026-05-06 · NCT05710237 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With Cancer Sunstone Medical · 2026-05-05 · NCT05947383 Induction Protocol for Psilocybin-Assisted Therapy in Treatment-Resistant Depression (TRD): A Pilot Study University of North Carolina, Chapel Hill · 2026-05-05 · NCT06303739 A Phase 2 Randomized Study Examining the Safety, Feasibility, and Effectiveness of Masking Psilocybin Therapy With General Anesthesia in Major Depressive Disorder Stanford University · 2026-05-05 · NCT07479550 An Exploratory Pilot Study of Palliadelic Treatment to Reduce Psychological Distress in People With Pancreatobiliary and Other Advanced Gastrointestinal Cancers University of Nebraska · 2026-05-05 · NCT05220046 A One-Year Observational Follow-up Study of Participants With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-Control Usona Institute · 2026-05-03 · NCT04353921 A Phase 2 Sequential Dose-Finding Study of Preparation for Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression University of Washington · 2026-05-03 · NCT07565909 Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord Injury James J. Peters Veterans Affairs Medical Center · 2026-05-03 · NCT07251491 Group Psilocybin-assisted Cognitive Behavioral Therapy for Major Depressive Disorder University of California, Los Angeles · 2026-05-03 · NCT07566104 Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder: A Randomized Controlled Trial Lakshmi N Yatham · 2026-04-30 · NCT06943573 Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic Effects Yale University · 2026-04-30 · NCT06624137 Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study) University Hospital, Basel, Switzerland · 2026-04-28 · NCT05883540 A Double-blind, Randomized Trial Examining the Preliminary Efficacy of Psilocybin Therapy for People With Chronic Low Back Pain Joshua Woolley, MD, PhD · 2026-04-28 · NCT05351541 Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder Portland VA Research Foundation, Inc · 2026-04-21 · NCT04982796 A Randomized, Double-Blind Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD) Usona Institute · 2026-04-21 · NCT03866174 Toward Patient-Tailored Care for Treatment-Resistant Depression: A Pilot Patient-Preference Clinical Trial of Music and Mindfulness in Psilocybin-Assisted Psychotherapy Kyle Greenway · 2026-04-21 · NCT07373535 Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence in Patients Diagnosed With Early-stage Breast Cancer and Ovarian Cancer in Remission University of Colorado, Denver · 2026-04-20 · NCT06430541 Open Label Psilocybin Brain Stimulation and Imaging Pilot Study Johns Hopkins University · 2026-04-19 · NCT06835699 Probing the Functional Magnetic Resonance Imaging Response to Psilocybin in Functional Neurological Disorder (PsiFUND) King's College London · 2026-04-16 · NCT05723276 CAPSI - Cancer Related Major Depression Treated With a Single Dose of Psilocybin: A Multicenter Randomized Placebo Controlled Double Blind Clinical Trial Section for Affective Disorders; Northern Stockholm Psychiatry · 2026-04-12 · NCT06319378 Safety Profile of 25 mg Psilocybin in Individuals With Cocaine Use Disorder University of California, Los Angeles · 2026-04-06 · NCT06102434 Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study) University of Wisconsin, Madison · 2026-04-02 · NCT06692192 Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of Psilocybin University of Wisconsin, Madison · 2026-04-02 · NCT05866471 Acute Analgesic Effects of DMT on Experimentally Induced Acute Nociceptive Pain, Hyperalgesia and Allodynia in Healthy Participants University Hospital, Basel, Switzerland · 2026-04-01 · NCT06180759 Effects of Psilocybin in Obsessive Compulsive Disorder Johns Hopkins University · 2026-04-01 · NCT05546658 Engaging Mood Brain Circuits With Psilocybin: a Randomized Neuroimaging Trial in Depression Sunnybrook Health Sciences Centre · 2026-03-29 · NCT06072898 Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder Indiana University · 2026-03-29 · NCT07499583 Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression Federal University of Latin American Integration · 2026-03-26 · NCT06898606 The QUANTUM Trip Trial - Psilocybin-assisted Therapy for Reducing Alcohol Intake in Patients With Alcohol Use Disorder: A Randomized, Double-blinded, Placebo-controlled Clinical Trial. Anders Fink-Jensen, MD, DMSci · 2026-03-23 · NCT05416229 Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects: A Randomized, Open-Label, Cross-Over Functional Magnetic Resonance Imaging Trial Medical University of Vienna · 2026-03-23 · NCT07490353 Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies University of New Mexico · 2026-03-19 · NCT07484906 Psilocybin for Treatment-Resistant Depression in Autism: a Pilot Trial With Pre-Post Brain and Cognitive Measurement to Understand Mechanism Centre for Addiction and Mental Health · 2026-03-19 · NCT06731621 Pilot Study of Psilocybin-assisted Treatment for Cannabis Use Disorder Johns Hopkins University · 2026-03-17 · NCT06660381 Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer: a Pilot Study Gustavo Vazquez · 2026-03-17 · NCT06818994 Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression: A Pilot Randomized Clinical Trial Centre for Addiction and Mental Health · 2026-03-17 · NCT07211438 Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's Disease Johns Hopkins University · 2026-03-15 · NCT04123314 Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder Johns Hopkins University · 2026-03-12 · NCT04620759 Exploratory Study of the Effects of Low-Dose Psilocybin on Sensory Processing, Neurophysiological Arousal, and Emotional Health University of Alabama at Birmingham · 2026-03-10 · NCT05227742 Psilocybin-facilitated Treatment for Chronic Pain University of Alabama at Birmingham · 2026-03-10 · NCT05068791 Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study Yale University · 2026-03-10 · NCT06442423 An Open-Label, Phase 1 Study of the Safety Pharmacokinetic Profile, and Preliminary Efficacy, of Organic Whole Psilocybin-Containing Mushrooms in Patients Suffering From PTSD Suzanne "Sue" Sisley MD · 2026-03-08 · NCT07275970 The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young Adults Region Skane · 2026-03-05 · NCT07169747 Pilot Proof of Concept Study Evaluating the Potential Psilocybin Assisted Psychotherapy (PAP) as a Therapeutic Tool for Patients Suffering From Severe Irritable Bowel Syndrome. NYU Langone Health · 2026-03-04 · NCT06760533 Examining the Safety and Clinical Efficacy of Psilocybin Therapy for Veterans With PTSD: An Open-Label Proof-of-Concept Trial Ohio State University · 2026-03-03 · NCT05554094 A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer. Psyence Australia Pty Ltd · 2026-03-02 · NCT07072728 Study of Psilocybin for Anorexia in Young Adults Marissa Raymond-Flesch, MD, MPH · 2026-03-02 · NCT06399263 Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought Johns Hopkins University · 2026-03-01 · NCT05301608 Does Psilocybin Change Synaptic Density in the Brains of Patients With Amnestic Mild Cognitive Impairment Centre for Addiction and Mental Health · 2026-02-24 · NCT06041152 The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers. Gabriella Gobbi · 2026-02-24 · NCT07433452 Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial Johns Hopkins University · 2026-02-22 · NCT06005662 Safety for Home Administration of Microdose Psilocybin Use Johns Hopkins University · 2026-02-22 · NCT06450210 Investigation of Psychedelic Effects in Psychoactive Substances Johns Hopkins University · 2026-02-22 · NCT06772753 Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care - PATH Study Yvan Beaussant, MD, MSci · 2026-02-16 · NCT04950608 A Phase 1 Translational Study to Assess Brain Activity Using Functional Magnetic Resonance Imaging (fMRI) and to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers MycoMedica Life Sciences PBC · 2026-02-12 · NCT07050368 Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability Johns Hopkins University · 2026-02-12 · NCT07053917 Single Dose Psilocybin for a Post-surgical Trauma Inpatient Population for Pain, Mood, and Opioid Use Disorder Trent Emerick · 2026-02-11 · NCT07406828 Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder: A Pilot Randomized Clinical Trial Centre for Addiction and Mental Health · 2026-02-11 · NCT07405606 Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers Hadassah Medical Organization · 2026-02-04 · NCT07079930 A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Oral Psilocybin (TRP-8802) Administration in Concert With Psychotherapy Among Adult Patients With Irritable Bowel Syndrome: A Randomized Delayed Treatment Control Design TRYP Therapeutics · 2026-02-04 · NCT06206265 Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER: a Pilot Study Nantes University Hospital · 2026-02-04 · NCT07391332 PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical Trial Bruyère Health Research Institute. · 2026-01-26 · NCT07063862 A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone Treatment NYU Langone Health · 2026-01-22 · NCT06796062 The STARLIGHT Protocol: State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma Baylor College of Medicine · 2026-01-21 · NCT06888128 A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant Depression COMPASS Pathways · 2026-01-11 · NCT05711940 Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis Johns Hopkins University · 2026-01-11 · NCT06656702 Behavioral and Neural Mechanisms Supporting Psilocybin-assisted Therapy for Phantom Limb Pain University of California, San Diego · 2026-01-08 · NCT05224336 A Randomized Double-blinded Controlled Trial for the Treatment of Persisting Symptoms After Concussion With Psilocybin-assisted Therapy: A Safety and Feasibility Trial University of Calgary · 2025-12-29 · NCT06615908 Microdosing Psychedelics to Improve Mood Rotem Petranker · 2025-12-29 · NCT05259943 Psilocybin in Chronic Low Back Pain: An Integrative Study of Lab-Based Mechanisms and Real-World Physical Therapy Outcomes Yale University · 2025-12-28 · NCT07306364 The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation Sheppard Pratt Health System · 2025-12-23 · NCT05220410 An Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality Disorder University of Chicago · 2025-12-22 · NCT05399498 Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter NYU Langone Health · 2025-12-21 · NCT07296328 Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use Disorder NYU Langone Health · 2025-12-18 · NCT06349083 A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant Depression COMPASS Pathways · 2025-12-17 · NCT05624268 Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced Cancer Yvan Beaussant, MD, MSci · 2025-12-15 · NCT06001749 Investigating the Effects of a Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm Behaviour: an Experimental Medicine Study Imperial College London · 2025-12-04 · NCT06798636 Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication in Patients With Chronic Pain: an Open-label Feasibility Study University of British Columbia · 2025-12-03 · NCT05585229 A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Psilocybin-assisted Psychotherapy on Psychiatric and Existential Distress in Advanced Cancer NYU Langone Health · 2025-12-03 · NCT05398484 Psilocybin vs Ketamine for Alcohol Use Disorder University of Iowa · 2025-11-27 · NCT06405607 Digital Intervention for Psychedelic Preparation (DIPP): A Randomised Controlled Feasibility Trial Comparing Meditation and Music-Based Programs in Healthy Volunteers. University College, London · 2025-11-25 · NCT06815653 Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive Disorder University of Texas at Austin · 2025-11-25 · NCT06132178 Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC): A Multicenter Triple-blind Phase 2 Randomized Controlled Trial of Psilocybin Therapy for Demoralized Adults Near the End of Life Charles S. Grob, M.D. · 2025-11-24 · NCT05403086 Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy Humans University of Zurich · 2025-11-18 · NCT06081179 A Double-blind, Phase II Feasibility Study to Assess the Safety and Efficacy of Psilocybin Microdosing Combined With Psychotherapy in Treatment-resistant Depression Beersheva Mental Health Center · 2025-11-18 · NCT07183748 Open Label, Phase 2 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe Obsessive Compulsive Disorder (OCD) in Drug and/or Psychotherapy Resistant Patients. Beersheva Mental Health Center · 2025-11-18 · NCT04882839 Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use Disorder Peggy C Nopoulos · 2025-11-16 · NCT05421065 Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder Yale University · 2025-11-04 · NCT03554174 A Phase 1/2 Study of a Group Model of Psilocybin-Assisted Therapy for Cancer-Related Anxiety in Patients With Metastatic Cancer University of Washington · 2025-11-04 · NCT05847686 Precision Functional Brain Mapping to Understand the Mechanisms of Psilocybin Washington University School of Medicine · 2025-10-30 · NCT04501653 A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety Ohio State University · 2025-10-29 · NCT06820723 A Wellcome Leap for the Opioid Crisis: Can the 5HT2A Agonist Psilocybin Improve Brain, Behavioral, and Clinical Outcomes in Opioid Use Disorder (OUD)? Anna Rose Childress, Ph.D. · 2025-10-28 · NCT06786325 Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults University of California, Berkeley · 2025-10-20 · NCT06367738 Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain University of California, Berkeley · 2025-10-20 · NCT05265546 Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on a Buprenorphine/Naloxone Formulation University of Wisconsin, Madison · 2025-10-14 · NCT04161066 A Phase 1 Study of a Second Psilocybin Group Retreat for Partial Responders With Anxiety Associated With Metastatic Cancer University of Washington · 2025-10-13 · NCT06644170 Psilocybin and Affective Function in Chronic Lower Back Pain Depression Johns Hopkins University · 2025-10-13 · NCT06355414 Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study Oregon Health and Science University · 2025-10-09 · NCT06988319 A Pilot Study in North Louisiana to Assess the Tolerability of Psilocybin as Well as Its Capacity to Promote Abstinence From Methamphetamine Kevin Murnane · 2025-10-06 · NCT06899594 Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ) Centre Hospitalier St Anne · 2025-10-06 · NCT07210112 Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment University Hospital, Geneva · 2025-10-01 · NCT07164287 Psilocybin and MDMA for Post-traumatic Stress Disorder (PTSD) Johns Hopkins University · 2025-09-30 · NCT06989957 An Exploratory Study of Feasibility, Efficacy, and Mechanisms of Mindfulness-Assisted Psychedelic Therapy University of Southern California · 2025-09-25 · NCT06233344